at Benzinga.com (Jan 13, 2015)
Amarin (AMRN +3.7%) is very close to receiving a long-sought patent on its lead drug candidate, AMR101, after the USPTO issues a Notice of Allowance supporting the use of the fish-oil heart pill in patients with high triglycerides. A Notice of Allowance is typically issued after regulators decide that a patent can be granted from an application. Next up is an FDA decision on AMR101, expected this month. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 19, 2014)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
at CNBC.com (Oct 17, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs